The General Hospital Corporation

Dana-farber-cancer Institute Inc.

Massachusetts Institute of Technology

Wyeth

Aalborg University

Other

Affymetrix, Inc.

Naar, Anders M.

Rajurkar, Mihir Shivadatta

Daniel Arie Haber

Shyamala Maheswaran

Raffaella Sordella

Jeffrey E Settleman

Daphne Winifred Bell

Pasi Antero Janne

Matthew Meyerson

Thomas J Lynch

William R Sellers

Juan Guillermo Paez

David T Ting

Bruce E Johnson

David Tomoaki Miyamoto

David E Housman

Alan J Buckler

Katherine M Call

Thomas M Glaser

Caryn Y Ito

Jerry M Pelletier

Elise A Rose

Nicola Aceto

Bruce E Johnston

Tanya Todorova

Xin Hong

Anders M Naar

Sridhar Krishna Rabindran

Andreas Petri

Sakari Kauppinen

Vivi Truong

Jonathan D Oliner

Mark Kalinich

Wendy Bruening

Andre Darveau

Nadia G Godin-Heymann

Eunice L Kwak

Francesca Bersani

Mihir Shivadatta Rajurkar

Mehmet Toner

Ravi Kapur

Doron Lipson

Fred C Christians

James Douglas Bean

Denis Paul Harkin

Zongli Zheng

Gromoslaw A Smolen

Tilak K Sundaresan

A John Iafrate

André Darveau

Wendy Breuning

David Miklos

Sean Lee

Sarah Javaid

David Tsai Ting

Tanya Todorova Kwan

This disclosure relates to new assay methods for analysis of RNA, e.g., from circulating tumor cells (CTCs), tumor-specific exosomes, or tumor-specific cell-free RNA, in a subject's blood sample to determine an expression level of one or more lineage markers in the blood sample, wherein the expression level of a specific one or more lineage markers is predictive of progression-free survival and overall survival for a specific anti-cancer treatment regimen in that subject.

Digital analysis of blood samples to determine efficacy of cancer therapies for specific cancers

Methods for treating cancer, e.g., cancer of epithelial origin, by specifically targeting human satellite II (HSATII) using sequence specific agents such as oligonucleotides.

Targeting human satellite II (HSATII)

Disclosed herein are methods and reagents for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) targeting treatment. The detection of these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.

Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments

This disclosure relates to new assay methods for analysis of circulating tumor cells (CTCs) in blood samples for detection, e.g., early detection, and/or monitoring of disease, e.g., cancer. The methods provide ultra-high sensitivity and specificity, and include the use of microfluidic isolation of CTCs and digital detection of RNA derived from the CTCs.

Digital analysis of circulating tumor cells in blood samples

Described herein are methods and assays relating to the presence and/or level of circulating tumor cells (CTCs). These CTC-Cs represent a highly metastatic subpopulation of CTCs. In some embodiments, the methods and assays described herein relate to the treatment of cancer.

Methods relating to circulating tumor cell clusters and the treatment of cancer

Methods for diagnosing cancer based on detecting the presence of increased levels of expression of satellite repeats and/or Line-1.

Biomarkers of cancer

Provided herein are assays and methods related to determining a ratio of expression levels of PSA/PSMA or determining the expression level of PSMA in circulating tumor cells for diagnosis and/or for the purpose of monitoring treatment efficacy for prostate cancers that are likely hormone resistant.

Diagnosis and monitoring treatment of prostate cancer

The technology described herein relates to methods of detecting circulating tumor cells (CTCs), e.g. by detecting changes in the expression of certain CTC marker genes. Aberrant expression of CTC marker genes, e.g. changes in expression indicative of CTCs can also be targeted in order to treat cancer.

Methods and assays relating to circulating tumor cells

Ultra-sensitive assays for the detection of mutations, e.g., from blood-based sources of tumor genetic material (circulating tumor cells or plasma), or other settings in which limiting amounts of DNA, e.g., tumor DNA, is available. The assay is exemplified in the estrogen receptor, but is broadly customizable to target mutations in other genes.

LNA-based mutant enrichment next-generation sequencing assays

The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB-569, HKI-272 and HKI-357.

Method for treating gefitinib resistant cancer

The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB 569, HKI-272 and HKI-357.

Methods for treating cancer, e.g., cancer of epithelial origin, by specifically targeting human satellite II (HSATII) using sequence specific agents such as oligonucleotides. As shown herein, the hetero chromatic HSATII satellite repeat is silenced in normal cells, but massively over expressed in epithelial cancers and in cancer cell lines when grown as xenografts or in 3D culture. Induction of HSATII RNA, either in xenografts or using in vitro reconstitution models, suggests the appearance of complementary DNA intermediates.

Growing community of inventors

Newton, MA, United States of America

Daniel Arie Haber